Fumax 40

Quick links to important sections

Fumax 40

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fumax 40

Quick Facts

Property Description
Active Ingredient Isosorbide Mononitrate
Form Oral tablet
Pharmacological Class Organic Nitrate / Systemic Vasodilator
General Purpose Prophylactic support for the heart
Origin Synthetic compound

Fumax 40 is a prescription-only cardiovascular medicine containing the single active ingredient Isosorbide Mononitrate. This synthetic compound is classified within the organic nitrate pharmacological group and functions as a systemic vasodilator to provide long-term heart support.

What Type of Medicine is Fumax 40?

Fumax 40 is an anti-anginal agent belonging to the nitrate class of drugs, which are chemically characterized as organic nitrates. The medicine acts by relaxing the smooth muscle in the walls of blood vessels. Its active substance, Isosorbide Mononitrate, is a synthetic entity, not a naturally occurring compound. The sustained efficacy of this ingredient is clinically recognized for its reliability in maintenance therapy. The number "40" refers to the precise milligram (mg) strength of the active component contained in the tablet.

Composition and Physical Form

Fumax 40 is manufactured as an oral solid dosage form—specifically, a tablet—and is intended for the oral route of administration. The composition consists exclusively of the Isosorbide Mononitrate active ingredient uniformly blended with standard solid pharmaceutical excipients, such as binders and fillers, forming the tablet matrix. Isosorbide Mononitrate is characterized by high, nearly 100% absolute bioavailability following oral administration. This high and predictable absorption rate is a key feature that supports its use as a prophylactic medication for adults.

What is the General Purpose of Fumax 40?

The general purpose of Fumax 40 is to reduce the heart’s workload and decrease its demand for oxygen, thereby contributing to cardiovascular stability. It accomplishes this by acting as a nitric oxide precursor to trigger the widening of blood vessels, which reduces the pressure the heart must pump against. This foundational action is applied in situations where long-term management of heart-related circulatory issues is required.

Regulatory References

  1. Isosorbide Mononitrate - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Fumax 40?

Possible side effects and safety information

The safety profile of Fumax 40 (Isosorbide Mononitrate) is based on official regulatory classifications, with documented adverse reactions primarily linked to its systemic vasodilating effect. Adverse reactions are grouped by frequency and affected body system, as established in government regulatory documents.

Frequency-Classified Adverse Reactions

Adverse reactions are classified according to official regulatory standards:

  • Very Common (ge 10%): Headache.
  • Common (1-10%): Dizziness, light-headedness, nausea, vomiting, hypotension, and reflex tachycardia.
  • Uncommon (0.1-1%): Flushing, rash, and pruritus (itching).
  • Very Rare (< 0.01%): Methemoglobinemia.

The most frequent effects, particularly headache, are often transient and documented to diminish or disappear after the first one to three weeks of continuous treatment. Effects such as hypotension and dizziness are also commonly observed at the start of therapy or following a dosage increase.

Serious Reactions and Safety Constraints

The official labeling documents rare but serious adverse reactions, including severe hypotension that can potentially lead to circulatory collapse or syncope. The medicine is strictly contraindicated in conditions such as marked anaemia, severe hypotension, and for concomitant use with Phosphodiesterase Type 5 (PDE-5) inhibitors (e.g., sildenafil or tadalafil) due to the risk of severe blood pressure drops.

Population-Specific Notes: Safety and efficacy have not been established in pediatric patients. Older adults should use the medicine with caution due to a potentially increased susceptibility to orthostatic effects and hypotension, as noted in the official prescribing information.

Overdose and Emergency Response

The official regulatory profile for Fumax 40 overdose defines the condition as an extreme extension of the drug's vasodilatory effects, leading to severe hemodynamic instability. Documented clinical manifestations are rooted in hypotension and reduced cardiac output, causing symptoms such as a severe throbbing headache, confusion, vertigo, syncope, and palpitations. Gastrointestinal effects listed in the regulatory documents include nausea, vomiting, and sometimes bloody diarrhea.

Immediate medical attention must be sought for any suspected overdose, particularly if symptoms of severe hypotension or compromised oxygen delivery are present. A severe, life-threatening outcome documented for nitrate overdose is methemoglobinemia.

Official emergency management is focused on increasing the central fluid volume by measures such as the administration of intravenous fluids and passive elevation of the patient's legs. The use of epinephrine and other vasoconstrictors is generally not recommended. When methemoglobinemia is diagnosed, Methylene Blue is the treatment of choice. Patients with underlying renal failure or congestive heart failure may require invasive monitoring due to the specific challenges of managing fluid volume in these populations.

Therapeutic Uses of Fumax 40

What Fumax 40 Treats: Main Uses and Benefits

Fumax 40 is commonly used for the long-term, prophylactic management of chronic stable angina pectoris, a condition marked by recurrent chest discomfort and pressure. The medication is used to help manage the recurrence of angina symptoms associated with coronary artery disease.

Quick Fact: Supports Management of Recurrent Chest Discomfort

The therapy helps address the overall frequency and intensity of these painful episodes, supporting patients whose symptoms may be predictable and linked to exertion. It is applied across therapeutic domains where additional symptomatic support is needed to address conditions presenting with episodic and fluctuating manifestations.

The medication is commonly used to help with the prophylaxis of stable angina and as a foundational component of maintenance therapy for patients diagnosed with Coronary Artery Disease (CAD). The medicine provides continuous support for managing symptoms related to systemic imbalance.

“This medication may assist with maintaining functional stability and can contribute to improved comfort during periods of symptomatic strain, supporting patients during episodes of heightened discomfort that interfere with routine activities.”

Fumax 40 contributes to easing the overall symptom load, helping patients cope more steadily with symptom fluctuations and supporting general well-being during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Fumax 40?

This section defines the official eligibility rules for using Fumax 40 (Isosorbide Mononitrate), based strictly on regulatory prescribing information. Eligibility is primarily established for the adult population receiving prophylactic support for angina.


Absolute Contraindications

Fumax 40 must not be used in patients with the following conditions, as they are absolute prohibitions:

  • Known Hypersensitivity to Isosorbide Mononitrate or other nitrates.
  • Concurrent use of Phosphodiesterase type-5 (PDE5) inhibitors (e.g., sildenafil) or the soluble guanylate cyclase (sGC) stimulator riociguat.
  • States of Acute Circulatory Failure, Cardiogenic Shock, or marked low blood pressure (systolic BP le 90 mmHg).
  • Marked Anaemia or Closed Angle Glaucoma.

Age and Physiological Restrictions

Population Regulatory Status
Children Use is not established; not recommended due to lack of safety and efficacy data.
Pregnancy Safety not established; use is not recommended unless considered essential.
Lactation Not recommended as excretion into breast milk is unknown.

Conditions Requiring Caution

Use requires special caution and monitoring in patients with pre-existing hypotension or volume depletion, and in those with Hypertrophic Cardiomyopathy or Severe Renal or Hepatic Impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documents for Fumax 40 (Isosorbide Mononitrate) detail specific interaction patterns, primarily centered on profound pharmacodynamic potentiation that affects blood pressure. All factual statements regarding restrictions are derived from government-approved labeling.

Absolute Contraindicated Combinations

Co-administration with certain medicinal products is formally prohibited due to the risk of severe, life-threatening hypotension and syncope. These combinations are restricted because they dramatically enhance the medicine’s vasodilating effects.

  • Phosphodiesterase Type 5 (PDE5) Inhibitors: This class of drugs, including sildenafil, tadalafil, vardenafil, and avanafil, must not be used concurrently.
  • Riociguat: The soluble guanylate cyclase (sGC) stimulator Riociguat is also formally contraindicated.

Clinically Significant Pharmacodynamic Potentiation

Additive blood pressure lowering is documented when Fumax 40 is co-administered with other agents that cause vasodilation or lower systemic blood pressure.

  • Antihypertensive Agents: Concurrent use with agents such as Beta-blockers, Calcium Channel Blockers, or ACE-inhibitors may lead to a potentiation of the hypotensive effect.
  • Other Vasodilators: The effects of other medicinal products that cause vasodilation are documented as being additive.
  • Alcohol (Ethanol): Additive vasodilating effects are documented with alcohol consumption, which may result in marked symptomatic orthostatic hypotension.

Pharmacokinetic and Population Considerations

Regulatory information notes that co-administration may increase the blood level of Dihydroergotamine. Furthermore, the risk of symptomatic hypotension from these interactions is specifically noted as being higher in patients who are volume-depleted.

Mechanism of Action

Molecular Activation and Nitric Oxide Generation

Fumax 40 (Isosorbide Mononitrate) acts as an inactive prodrug that must first undergo enzymatic bioactivation inside vascular cells. The compound is reduced by the mitochondrial enzyme Aldehyde Dehydrogenase-2 (ALDH2), which liberates the key signaling molecule: Nitric Oxide (NO). This enzymatic conversion initiates the predictable molecular cascade.

Systemic Vasodilation and Preload Reduction

The released Nitric Oxide activates its primary molecular target, Soluble Guanylate Cyclase (sGC), triggering a cellular cascade that increases the second messenger cGMP and causes smooth muscle relaxation. This effect is most pronounced in the systemic veins, leading to widespread venodilation and peripheral blood pooling. This pooling reduces the volume of blood returning to the heart (cardiac preload), leading to a decrease in myocardial wall tension and subsequent modulation of oxygen consumption.

Mechanism Limitation: Nitrate Tolerance

The mechanism is subject to a biological constraint known as nitrate tolerance (tachyphylaxis), where the required enzymatic activity may be functionally inhibited or saturated upon continuous, uninterrupted exposure. This is thought to involve the essential ALDH2 enzyme, preventing the conversion of the drug into the Nitric Oxide signaling molecule.

Dosage and Administration Information

The administration guidelines for Isosorbide Mononitrate (Fumax 40) are primarily structured around the need to incorporate a daily period free of the medication, a measure required to prevent the body from developing pharmacological tolerance. This core principle dictates the required frequency and timing for both oral formulations.

Dosing and Frequency

Fumax 40 is strictly for oral administration and is available in both immediate-release (IR) and extended-release (ER) tablet forms.

Formulation Dosing Schedule Frequency Constraint
Immediate-Release Starting dose: 5 mg to 10 mg twice daily. Maintenance dose: 20 mg twice daily. Doses must be separated by a 7 hr interval to ensure a sufficient nitrate-free period.
Extended-Release Starting dose: 30 mg or 60 mg once daily. Must be taken once daily in the morning upon arising.

Administration Requirements

The Extended-Release Tablet must be swallowed whole with fluid and is not to be crushed, split, or chewed, as this would interfere with the controlled-release mechanism. Immediate-release tablets may be taken with or without food.

Population Rules and Cessation

Treatment in older adults is generally initiated at the low end of the dosing range. For patients with renal or hepatic impairment, caution and potential dose reduction are indicated. Treatment must not be stopped abruptly; both the dosage and frequency must be gradually tapered when cessation is required. Safety and efficacy have not been established for pediatric patients (under 18 years of age).

Recent Clinical Evidence

Evidence for Use in Chronic Stable Angina Pectoris

Research examining Fumax 40 was conducted for its use in patients with chronic stable angina pectoris, a condition characterized by fluctuating or episodic manifestations of chest discomfort. The primary evidence derives from Randomized Controlled Trials (RCTs), where patients were observed over defined time intervals and their outcomes were monitored against a control group, which often included placebo. These trials, along with subsequent systematic reviews, contribute to the broader evidence landscape related to this condition.

Studies explored two main types of outcomes related to physical discomfort and functional capacity. Researchers monitored outcomes related to episodic or acute changes by tracking the number of angina episodes patients experienced per week and monitoring the use of short-acting relief medications. Separately, functional outcomes were measured during standardized exercise tests, where researchers monitored how long it was observed to take before patients experienced symptoms, reflecting daily functioning or activity level. Findings from these short-term studies contribute to understanding symptom patterns in the observed populations.

Long-Term Evidence and Durability of Study Findings

Research was also conducted to explore the durability of the findings over extended periods. Studies monitored patient responses over time to examine if the patterns observed in short-term studies were sustained during long-term use for maintenance therapy. This research focus is relevant in trials assessing short-term or episodic symptom patterns, and data show patterns related to sustained outcomes only when administered according to a schedule that included a nitrate-free interval.

A significant portion of the evidence describes patterns observed regarding the potential for the medicine's activity to diminish with continuous, non-stop administration. Studies focusing on this issue report how symptoms evolved in the observed populations when the medicine was used without a scheduled break, leading researchers to investigate time-off periods (nitrate-free intervals) as a factor in sustaining the observed patterns of change. Research highlights that administering a daily nitrate-free interval was associated with patterns related to sustaining the described outcomes. However, the precise requirements for this time-off period may vary and are still being explored in research.

Evidence in Special Populations

Fumax 40 was evaluated primarily in adult patients diagnosed with chronic stable angina. This research provides context but not individual predictions, as results apply only to the populations studied.

For the older adult population, research describes the medicine's evaluation in this age group, as these patients were included in general adult trials. However, dedicated, large-scale studies specifically monitoring outcomes for older adults with multiple complex co-existing conditions are limited. Furthermore, there is limited information regarding long-term outcomes and safety for children, as the medicine has not been studied for use in the pediatric population. Data for women who are pregnant or nursing also remain insufficient, and specific clinical evidence has not been evaluated.

Research Gaps and Areas of Uncertainty

The evidence base contributes to understanding symptom patterns, but several key limitations have been noted in peer-reviewed literature and regulatory summaries. The follow-up durations were limited in many of the core RCTs, meaning long-term outcomes beyond several months are not fully established or consistently characterized across all research.

While research suggests that the short-term findings were associated with patterns in symptom metrics and exercise capacity, certainty remains low regarding the consistency of patient-reported outcomes describing perceived discomfort. Findings were mixed in some studies attempting to capture phases of heightened symptom activity, and the data for certain complex patient groups remain insufficient. This evidence highlights what is known—and what is still uncertain—about this medicine's research foundation.

Key Studies & References

  1. Isosorbide Mononitrate Extended-Release Tablets, USP (Official US Labeling/Monograph)
  2. Isosorbide - StatPearls (National Center for Biotechnology Information Bookshelf)
  3. The Role of Nitrates in the Management of Stable Ischemic Heart Disease: A Review of the Current Evidence and Guidelines

Frequently Asked Questions (FAQ)

Common questions about Fumax 40 (FAQ)


Q: Is Fumax 40 considered a pain reliever?

Official documents classify Fumax 40 as an anti-anginal agent and a nitrate vasodilator. Its purpose is to prevent the symptoms of chest discomfort (angina) by reducing the workload on the heart. It functions through widening blood vessels rather than directly relieving sudden, acute pain.


Q: How quickly does Fumax 40 typically start to work?

Official regulatory information indicates that the active substance reaches its maximum concentration in the blood within approximately 30 to 60 minutes. However, Fumax 40 is a prophylactic medicine, meaning it is intended for the prevention of symptoms through sustained use. It is not formulated to be quick-acting relief for sudden, acute symptoms.


Q: Do most people experience a change in appetite with Fumax 40?

Official safety reports show that common side effects are often related to the digestive system, such as nausea and vomiting. Less common or infrequent events described in certain regulatory documents include decreased appetite or loss of weight. Patients who observe a significant or concerning change in appetite are advised in patient information to contact their healthcare provider.


Q: Can taking Fumax 40 affect my sleep schedule?

Regulatory documents that detail adverse events indicate that side effects related to the nervous system, such as insomnia (trouble sleeping) and nightmares, have been reported. These are classified as infrequent effects. Patients experiencing new or worsening sleep issues should report these observations to their healthcare provider.


Q: What happens if I forget to take Fumax 40 one day?

Official guidance states that if a dose is missed, it can be taken as soon as the lapse is noticed. If, however, the next dose is due shortly, the instruction is to skip the missed dose. The guidance prohibits taking a double dose to make up for a missed dose.


Q: Does Fumax 40 contain any dairy or gluten ingredients?

Regulatory documents list the active and inactive ingredients (excipients) in the formulation, which can sometimes include substances like lactose, a sugar found in milk. Because the specific excipients can vary between manufacturers and formulations, patients requiring verification of specific excipients, such as for dairy or gluten allergies, are directed by official sources to check the detailed list provided in the specific package insert.


Q: Is Fumax 40 known to cause weight gain?

Based on regulatory safety data, weight change is not listed as a common or frequent side effect. Some comprehensive safety lists describe instances of decreased weight in a low frequency of patients. Weight gain is not commonly documented in the official adverse event profile.


Q: Does Fumax 40 treat the cause or just the symptoms?

Fumax 40 is a prophylactic medicine used for long-term management and prevention of symptoms. Its mechanism works to reduce the heart's workload by promoting vasodilation (widening of blood vessels), thereby relieving the functional strain that leads to symptoms. Regulatory documents define its role as managing and preventing symptoms, not curing the underlying medical condition.


Q: How long does Fumax 40 stay in your system after stopping it?

According to pharmacological data, the active ingredient, Isosorbide Mononitrate, has an elimination half-life of approximately five hours. This means that after five hours, about half the drug has been processed and removed by the body. Full clearance from the system requires multiple half-lives.


Q: Why is Fumax 40 available in different strengths?

Official dosing instructions explain that treatment is typically started at a lower strength. The availability of multiple strengths allows a healthcare provider to find the most appropriate and effective maintenance level for the patient. This practice, known as titration, ensures the medicine is administered at the lowest strength necessary to achieve the desired effect.


Q: Can I take ibuprofen or acetaminophen while using Fumax 40?

Official regulatory documents do not list common over-the-counter pain medicines, such as ibuprofen or acetaminophen, as absolute contraindications. However, combining Fumax 40 with any other medicine can potentially lead to unforeseen effects or interactions, particularly with NSAIDs like ibuprofen. The standard regulatory guidance is to fully disclose all medicines, including over-the-counter products, to a healthcare provider before use.


Q: Can Fumax 40 affect the results of blood tests?

Certain patient information leaflets and regulatory sources note that taking this medication may interfere with the accuracy of specific laboratory test results, such as cholesterol levels. Official documents state the necessity of informing laboratory personnel and healthcare professionals about the use of this medicine.


Q: Is Fumax 40 a controlled substance?

Official drug classification records confirm that Fumax 40, which contains Isosorbide Mononitrate, is a prescription medicine but is not classified as a federally controlled substance. This classification is determined by government agencies based on the potential for misuse or addiction.


Q: Does Fumax 40 interact with herbal supplements?

Regulatory documents warn about potential interactions with various co-administered substances. While the labels do not list every known herbal supplement, a general caution is given regarding potential additive effects with other medicines. Regulatory guidance emphasizes the importance of disclosing all herbal or vitamin supplements to the prescribing doctor.


Q: What is the risk of dependence or addiction with Fumax 40?

Official safety information states that a type of physical dependence has been observed in industrial workers exposed to high, continuous levels of organic nitrates, but the relevance to clinical dosing is uncertain. To prevent a potential rebound phenomenon, official instructions strictly mandate that the medicine be gradually reduced in dosage rather than stopped suddenly.


Q: Are there different names for Fumax 40 in other countries?

The active ingredient in this medicine is globally recognized by its chemical name, Isosorbide Mononitrate. The brand name, Fumax 40, is specific to the approval in certain regions. In other countries, the medicine may be sold under different trade names, but it will contain the same active chemical substance.


Q: Can I drive or operate machinery after taking Fumax 40?

Official patient safety information includes a warning that this medicine can affect judgment, coordination, and reaction time. Regulatory guidance advises against driving or operating complex machinery until a person understands the personal impact of the medicine, due to the documented risk of dizziness or fainting.


Q: What if I'm already taking a multivitamin; does that interact with Fumax 40?

Standard multivitamin supplements are not typically documented in core regulatory interactions as having a major effect on Fumax 40. Official patient information emphasizes the need for individuals to review their entire list of medicines, including all supplements and vitamins, with their healthcare team.


Q: How often do people need to see their doctor while on Fumax 40?

Official regulatory guidance notes that patients should keep all medical and lab appointments while using this medication. Monitoring, which may include regular blood pressure checks or other tests, is advised. The specific frequency of check-ups is not standardized but is determined by the individual patient's condition and the discretion of their prescribing doctor.


Q: What if I have an allergic reaction to a different drug; can I still take Fumax 40?

Official regulatory documents state that this medicine is strictly prohibited only for individuals with a known allergy (hypersensitivity) to Isosorbide Mononitrate or other nitrate-class drugs. A previous allergy to a medicine from an unrelated chemical group is not automatically an absolute prohibition, but official safety warnings emphasize that all known allergic reactions must be fully disclosed to the prescribing doctor.


Q: How is Fumax 40 different from other similar treatments mentioned in the news?

Fumax 40 is a specific prescription medicine containing the single active ingredient Isosorbide Mononitrate. Official classification places it within the Organic Nitrate pharmacological group. Its function is defined as a systemic vasodilator used for long-term prophylactic support in the management of chronic conditions.

How should Fumax 40 be stored and disposed of?

Official Storage and Disposal Requirements

Fumax 40 (Isosorbide Mononitrate oral tablet) must be stored strictly according to government-approved labeling to maintain product stability.

Storage Requirement Condition
Temperature Range Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Environmental Protection Keep the container tightly closed to protect the tablets from moisture.
Child Safety Mandatory to store the medication out of the sight and reach of children.

Disposal Instructions

Unused or expired Fumax 40 should be disposed of via a formal medicine take-back program if one is available. If a take-back program is not accessible, regulatory guidelines instruct mixing the tablets with an undesirable substance (such as dirt or coffee grounds) and sealing the mixture in a bag before discarding it with household trash. The medication should not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Fumax 40 found in:

A-Z Index: